TechBio x AI Drug Discovery

In 2025, TechBio is moving from concept to reality. The era of theory is giving way to execution: platforms deliver pipelines, automation drives reproducibility, and partnerships transition from pilots to multi-step agreements, as explored in this report in partnership with Speedinvest.

Key findings

• European techbio and AI drug discovery startups raised over $2B in 2025, up from $1.6B in 2024, driven by Isomorphic Labs' $600M round.
• Phase I-III trials account for 62% of drug development costs but drew only $298M of VC funding in 2024-2025, while target discovery took $1.8B for 3% of costs.
• European clinical trial tech startups are projected to raise $202M in 2025, ten times the 2015 total of $19M.
• Chemical synthesis, a segment that first drew funding in 2018, passed $200M in Europe in 2025, up from $73M in 2024, led by CuspAI's $100M Series A.
• Europe's 250+ techbio and AI drug discovery university spinouts have raised $5.8B since 2020 and are worth $24.6B combined, up 3.5x since 2019.